Scancell (LON:SCLP) Stock Price Passes Below 200 Day Moving Average - Here's What Happened

Key Points

• Scancell Holdings plc's stock price fell below its 200-day moving average of GBX 9.62, closing at GBX 8.50 with a 3.2% decline in value during trading.
• The company has a market capitalization of £85.82 million, with a negative price-to-earnings ratio of -397.60 and a significant insider ownership of 15.15%.
• Insider Martin Diggle purchased 102,236 shares at an average price of GBX 11 per share on August 7, indicating continued interest from company insiders despite the stock's recent performance.

Scancell Holdings plc (LON:SCLP - ) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 9.62 ($0.13) and traded as low as GBX 8.50 ($0.12). Scancell shares last traded at GBX 8.50 ($0.12), with a volume of 1,458,022 shares.

Scancell Stock Down 3.2%

The firm has a market cap of £85.82 million, a price-to-earnings ratio of -397.60 and a beta of 0.35. The firm's 50 day moving average price is GBX 10.11 and its two-hundred day moving average price is GBX 9.62. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01.

Insider Buying and Selling at Scancell

In other Scancell news, insider Martin Diggle bought 102,236 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was acquired at an average price of GBX 11 per share, for a total transaction of £11,245.96. Company insiders own 15.15% of the company's stock.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.